Q2 2024 EPS Estimates for Werewolf Therapeutics, Inc. Decreased by Analyst - MarketBeat
HOWL Stock | USD 1.54 0.03 1.91% |
About 61% of Werewolf Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Werewolf Therapeutics suggests that many traders are alarmed. Werewolf Therapeutics' investing sentiment shows overall attitude of investors towards Werewolf Therapeutics.
Werewolf |
Q2 2024 EPS Estimates for Werewolf Therapeutics, Inc. Decreased by Analyst MarketBeat
Read at news.google.com
Werewolf Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Werewolf Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Werewolf Therapeutics Fundamental Analysis
We analyze Werewolf Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Werewolf Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Werewolf Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Werewolf Therapeutics stock to make a market-neutral strategy. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics with similar companies.
Peers
Werewolf Therapeutics Related Equities
FATE | Fate Therapeutics | 1.19 |
| ||
KPTI | Karyopharm Therapeutics | 3.23 |
| ||
CRBU | Caribou Biosciences | 5.59 |
| ||
HOOK | Hookipa Pharma | 6.40 |
|
Check out Werewolf Therapeutics Hype Analysis, Werewolf Therapeutics Correlation and Werewolf Therapeutics Performance. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.